Glicetile

Each capsule contains Choline Alfoscerate 400 mg.

Pharmacology: L-alpha-glycerylphosphorylcholine, also called choline alfoscerate, is a phospholipid metabolite.
After oral administration of choline alfoscerate (1200 mg) in healthy young volunteers, mean free plasma choline increased quickly (from 10.1±0.66 μM/L at 0 h to 13.6±1.04 μM/L at 2 h); the Cmax was reached in about 3 hours (14.2±1.66 μM/L) and the values recorded remained higher than basal for about 10 hours.
After oral administration, choline alfoscerate is cleaved within gut mucosal cells, by the action of glycerylphosphoryl-choline diesterase (L-3-glyceryl-phosphorylcholine glycerophosphohydrolase), into glycerylphosphate and free choline, which enters the portal circulation and can reach brain tissues, where it is incorporated into the phospholipid fraction of the neuronal plasma membrane and into microsomes. In the brain, the concentration of choline alfoscerate increases slowly and attains maximum levels 8 hours after administration, thereafter remaining constant over 30 hours.
Pharmacodynamics: Mechanism of Action: Choline alfoscerate is involved in brain phospholipid metabolism, being cleaved by the enzyme glycerylphosphorylcholine diesterase into a molecule of choline and another of glycerol-1-phosphate. Choline can be used for synthesizing acetylcholine whereas glycerol-1-phosphate, after phosphorylation, can enter the phospholipid pool. Activation of these pathways could provide both free choline and phospholipids for synthesizing acetylcholine and reconstituting nerve cell membrane components. On the other hand, both choline kinase and phosphocholine acyltransferase are able to covert choline into phospholipids. Choline alfoscerate is therefore a source of choline of the same form that a cell would obtain scavenging its own membranes and probably the form of choline that neurons use for synthesizing acetylcholine when larger amounts of choline are required, or when it is poorly available.
Pharmacokinetics: Absorption and distribution: After oral administration, absorption is 88%. Readily crosses the blood-brain barrier and accumulates mainly in the brain (the concentration reaches 45% of the level in blood plasma), lung and liver.
Metabolism and excretion: In the body of choline alfoscerate enzymatically biotransformed to choline and glycerophosphate (providing the pharmacological effects of the drug). 85% is excreted in the lungs as carbon dioxide, the remaining part (15%) is excreted in the urine and feces.

Degenerative brain syndromes psicoorganiche-involutional or secondary to cerebrovascular insufficiency, or cognitive disorders of the elderly characterized by primary or secondary memory deficits, confusion and disorientation, loss of motivation and initiative from and reduction of attentional capacity.
Alterations in the affective sphere and senile behavior: emotional lability, irritability, indifference to its surroundings.
Senile pseudodepression.

The usual oral dose is 400 mg, 2-3 times a day. Dosage may be adjusted according to the patient's symptoms.

No data available.

Patients who have shown hypersensitivity to this product or any of its components.
Pregnant women or women of childbearing potential.

Effects On Ability To Drive And Use Machines: No data available.

Use of the drug during pregnancy and lactation (breastfeeding) is contraindicated.

Any nausea (probably due to a secondary dopaminergic activation) may require dosage reduction.
Digestive system: gastritis, gastrointestinal disease.
CNS: drowsiness, insomnia, antagonism, nervousness, convulsion, hyperkinesia.

Store at temperatures not exceeding 30°C.

Nootropics & Neurotonics/Neurotrophics

N07AX02 - choline alfoscerate ; Belongs to the class of other parasympathomimetics.

Rx